Our top pick for
Building a portfolio
Houlihan Lokey, Inc is a capital markets business based in the US. Houlihan Lokey shares (HLI) are listed on the NYSE and all prices are listed in US Dollars. Houlihan Lokey employs 1,491 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$52.00 - $72.88|
|50-day moving average||$67.50|
|200-day moving average||$66.60|
|Wall St. target price||$72.00|
|Dividend yield||$1.28 (1.86%)|
|Earnings per share (TTM)||$4.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Houlihan Lokey stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Houlihan Lokey's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Houlihan Lokey's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Houlihan Lokey shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Houlihan Lokey's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.54. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Houlihan Lokey's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||25.3%|
|Gross profit TTM||$1.1 billion|
|Return on assets TTM||14.89%|
|Return on equity TTM||23.68%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
There are currently 2.1 million Houlihan Lokey shares held short by investors – that's known as Houlihan Lokey's "short interest". This figure is 6.6% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Houlihan Lokey shares can be evaluated.
Houlihan Lokey's "short interest ratio" (SIR) is the quantity of Houlihan Lokey shares currently shorted divided by the average quantity of Houlihan Lokey shares traded daily (recently around 324043.37899543). Houlihan Lokey's SIR currently stands at 6.57. In other words for every 100,000 Houlihan Lokey shares traded daily on the market, roughly 6570 shares are currently held short.
However Houlihan Lokey's short interest can also be evaluated against the total number of Houlihan Lokey shares, or, against the total number of tradable Houlihan Lokey shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Houlihan Lokey's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Houlihan Lokey shares in existence, roughly 30 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Houlihan Lokey shares, roughly 41 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Houlihan Lokey.
Find out more about how you can short Houlihan Lokey stock.
Dividend payout ratio: 32.18% of net profits
Recently Houlihan Lokey has paid out, on average, around 32.18% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.92% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Houlihan Lokey shareholders could enjoy a 1.92% return on their shares, in the form of dividend payments. In Houlihan Lokey's case, that would currently equate to about $1.28 per share.
While Houlihan Lokey's payout ratio might seem fairly standard, it's worth remembering that Houlihan Lokey may be investing much of the rest of its net profits in future growth.
Houlihan Lokey's most recent dividend payout was on 14 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 February 2021 (the "ex-dividend date").
Over the last 12 months, Houlihan Lokey's shares have ranged in value from as little as $52.0035 up to $72.8796. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Houlihan Lokey's is 0.7071. This would suggest that Houlihan Lokey's shares are less volatile than average (for this exchange).
Houlihan Lokey, Inc. , an investment banking company, provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services worldwide. It operates in three segments: Corporate Finance, Financial Restructuring, and Financial Advisory Services. The Corporate Finance segment offers general financial advisory services; and advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions, as well as financial sponsors on various transactions. It also provides financing solutions and capital-raising advisory services for publicly-held and multinational corporations, financial sponsors, and privately-held companies. The Financial Restructuring segment advises debtors, creditors, and other parties-in-interest related to recapitalization/deleveraging transactions. It also provides a range of advisory services, including structuring, negotiation, and confirmation of plans of reorganization; structuring and analysis of exchange offers; corporate viability assessment; dispute resolution and expert testimony; and procuring debtor-in-possession financing.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.